The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This analysis examines monkeypox (MPX) cases and vaccinations by race/ethnicity based on national data obtained from the Centers for Disease Control and Prevention (CDC). We find that while the current MPX outbreak in U.S. appears to be slowing down, disparities persist among Black and Hispanic people.
In the wake of the FDA's emergency use authorization for COVID-19 vaccines for children ages 6 months through 4 years old, many parents remain hesitant to vaccinate their children in this age group, with a slight majority saying they view the vaccine as a bigger risk to their child's health than getting infected with coronavirus.
If the federal government runs out of money to purchase COVID-19 vaccines, the per-dose price likely would skyrocket and could increase spending on vaccines by billions of dollars a year, a new KFF analysis finds.
Amid controversies around the COVID-19 vaccine and growing distrust of public health authorities, more than four in ten Republicans and Republican-leaning independents, and a third of parents, now say they oppose requiring children in public schools to receive some childhood vaccines, up since 2019, a new KFF COVID-19 Vaccine Monitor survey finds.
This analysis examines monkeypox vaccine allocations and jurisdictional requests. It explores jurisdictional request rate (the number of vaccine does requested as a share of the jurisdiction’s allocation from HHS) for JYNNEOS, the preferred vaccine. Overall, while most jurisdictions have requested at least their full supply, some are well below that mark, raising questions about how quickly their at-risk populations can get protected.
This post provides updated estimates the number of people who are not up-to-date on COVID-19 vaccination living in counties designated by the CDC as being "high" or "medium" COVID-19 community levels. These are areas of elevated risk, with relatively high levels of new COVID-19 cases and strained hospital capacity. This analysis finds that the number of those not up to date on COVID-19 vaccination, and the most at risk for severe illness, living in areas of elevated risk has grown since early June 2022.
With the FDA authorization of both Moderna and Pfizer’s COVID-19 vaccine for children between the ages of 6 months and 5, the last major phase of the U.S. vaccination roll-out is underway. This brief provides an overview of the characteristics of children under the age of 5 and discusses some issues to consider in rolling out vaccination to this age group.
This data note describes COVID-19 vaccination rates of nursing facility residents and staff between August 2021 and the week ending September 18th, 2022. We briefly explore how federal policy actions have affected vaccine take-up thus far, and what that might mean for take-up of the new, bivalent boosters.
The KFF-Washington Post partnership Survey of Parents explores experiences and views pertaining to childhood vaccines. The Survey of Parents also sheds light on school vaccination requirements, views on federal health agencies and policy changes, and the views of parents with children diagnosed with autism spectrum disorder. This poll comes as the Trump administration revamps federal policies, and HHS Secretary Robert F. Kennedy Jr. continues to question the childhood vaccine schedule.
Children between the ages of 6 months and 5 years of age finally became eligible for COVID-19 vaccination in the U.S. on June 18, after the Director of the Centers for Disease Control and Prevention (CDC) recommended their use for this population, following emergency use authorization granted by the Food and Drug Administration. Here, we examine the status of vaccine uptake in this group, one month into their eligibility.
© 2026 KFF